Edgewise Therapeutics (EWTX) Valuation Check After Strong Multi Year Shareholder Returns

Simply Wall St.04-25 21:11

Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630053818?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-04-25 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630053818","market":"us","top_or_hot":-1,"title":"Edgewise Therapeutics (EWTX) Valuation Check After Strong Multi Year Shareholder Returns","media":"Simply Wall St.","content":"<div>\n<p>Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-valuation-check-after-strong-mult\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics (EWTX) Valuation Check After Strong Multi Year Shareholder Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics (EWTX) Valuation Check After Strong Multi Year Shareholder Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-25 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-valuation-check-after-strong-mult><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-valuation-check-after-strong-mult\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWTX","symbol_name":"Edgewise Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-valuation-check-after-strong-mult","article_id":"2630053818","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-valuation-check-after-strong-mult","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630053818","pubTimestamp":1777122697,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile.\nSee our latest analysis for Edgewise Therapeutics.\nRecent trading has been choppy, with a 1 day share price return of 1.12% and a 7 day share price return of an 8.28% decline. However, momentum over the past 90 days and year to date remains positive, supported by a 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWTX":"Edgewise Therapeutics, Inc.","BK4539":"次新股","BK4007":"制药"},"translate_title":"Edgewise Therapeutics(EWTX)多年股东回报强劲后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1.5},"content_text":"Edgewise Therapeutics (EWTX) has drawn investor attention after recent trading left the stock around $31.58, with returns showing mixed short term moves but a strong year to date and 1 year profile. See our latest analysis for Edgewise Therapeutics. Recent trading has been choppy, with a 1 day share price return of 1.12% and a 7 day share price return of an 8.28% decline. However, momentum over the past 90 days and year to date remains positive, supported by a 1 year total shareholder return of 112.80% and a 3 year total shareholder return of 260.09%. If this kind of move has you looking beyond a single name, it could be a moment to scan the market for other healthcare focused AI opportunities via the 33 healthcare AI stocks. With Edgewise Therapeutics posting strong multi year shareholder returns and trading around $31.58, the key question now is simple: is the stock still undervalued or is the market already pricing in future growth? AdvertisementPreferred Price-to-Book of 6.5x: Is it justified? At a last close of $31.58, Edgewise Therapeutics trades on a P/B of 6.5x, which is high relative to the broader US pharmaceuticals group but lower than its closer peer set. P/B compares the share price to the company’s book value per share, so it is often used for early stage or loss making biopharma businesses where earnings are not yet meaningful. For Edgewise Therapeutics, this 6.5x P/B indicates that the market is assigning a premium to the asset base and pipeline, despite the company reporting a loss of $167.80m, no meaningful revenue and forecasts that it will remain unprofitable over the next 3 years. Compared with the US pharmaceuticals industry average P/B of 2.4x, Edgewise Therapeutics trades at a much richer level, although it screens as cheaper than its immediate peers which average 22.5x. That contrast highlights how sensitive these valuations can be to expectations around drug development progress, funding and eventual commercialization outcomes. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 6.5x (OVERVALUED). However, there are clear pressure points here, including the company’s $167.80m loss, its lack of current revenue, and the inherent uncertainty around clinical trial outcomes. Find out about the key risks to this Edgewise Therapeutics narrative. Next Steps If this mix of strength and pressure points leaves you on the fence, it could be time to check the numbers yourself and move quickly to form your own view. You might start with a closer look at the company's 3 important warning signs. Looking for more investment ideas? If Edgewise Therapeutics has caught your attention, do not stop there. Broaden your watchlist with a few focused stock ideas that fit different goals.  Target potential mispricing by scanning 56 high quality undervalued stocks that combine strong fundamentals with prices the market may not fully appreciate yet. Strengthen your income stream by reviewing 13 dividend fortresses that aim to pair higher yields with more resilient payout profiles. Cut down on unwelcome surprises by checking 72 resilient stocks with low risk scores that score better on financial strength and risk measures.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Edgewise Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630053818","isCrawlerRequest":true}